This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fagan TJ . Nomogram for Baye’s Theorem. N Engl J Med 1975; 293: 257.
Griner PF, Mayewski RJ, Mushlin AI, Greenland P . Selection and interpretation of diagnostic tests and procedures. Ann Intern Med 1981; 94: 557–592.
Marr KA, Leisenring W . Design issues in studies evaluating diagnostic tests for Aspergillosis. Clin Infect Dis 2005; 41 (suppl): S381–S386.
Donnelly JP, Leeflang MM . Galactomannan detection and diagnosis of invasive Aspergillosis. Clin Infect Dis 2010; 50: 1070–1071.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al. Posaconazole vs Itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348–359.
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335–347.
Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471–5489.
Sánchez-Ortega I, Patiño B, Arnan M, Peralta T, Parody R, Gudiol C et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2011; 46: 733–739.
Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B, Fernández de Sevilla A et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 2014; 59: 1696–1702.
Cornely OA . Galactomannan testing during mold-active prophylaxis. Clin Infect Dis 2014; 59: 1703–1704.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821.
Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250.
Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042–1051.
Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28: 667–674.
Aguado JM, Vázquez L, Fernández-Ruiz M, Villaescusa T, Ruiz-Camps I, Barba P et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive Aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis 2015; 60: 405–414.
Acknowledgements
This study was partly supported by an unrestricted research grant from Schering Plough.
Author contributions
RFD, ISO and MCE are responsible for the conception and design of the study and wrote the initial draft of this manuscript. All authors contributed to the execution of the study, the analysis and/or interpretation of the data, reviewed the manuscript content and approved the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
MA, RFD and ISO have received consultation and/or speaker fees from Esteve, Gilead Science, Merck Sharp & Dohme, Pfizer and/or Schering Plough during the study period. MCE has received grant support from Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp and Dohme, Pfizer, Schering Plough, Soria Melguizo SA and Ferrer International, has been an advisor/consultant to Astellas Pharma, Gilead Sciences, Merck Sharp and Dohme, Pfizer and Schering Plough, and has received honoraria for talks on behalf of Gilead Sciences, Merck Sharp and Dohme, Pfizer, Astellas Pharma and Schering Plough. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Duarte, R., Sánchez-Ortega, I., Arnan, M. et al. Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study. Bone Marrow Transplant 52, 326–329 (2017). https://doi.org/10.1038/bmt.2016.279
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.279
This article is cited by
-
Impact of posaconazole prophylaxis and antifungal treatment on BAL GM performance in hematology malignancy patients with febrile neutropenia: a real life experience
European Journal of Clinical Microbiology & Infectious Diseases (2024)